Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

206 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Incongruity between T cell receptor recognition of breast cancer hotspot mutations ESR1 Y537S and D538G following exogenous peptide loading versus endogenous antigen processing.
Shafer P, Leung WK, Woods M, Choi JM, Rodriguez-Plata CM, Maknojia A, Mosquera A, Somes LK, Joubert J, Manliguez A, Ranjan R, Burt B, Lee HS, Zhang B, Fuqua S, Rooney C, Leen AM, Hoyos V. Shafer P, et al. Among authors: fuqua s. Cytotherapy. 2024 Mar;26(3):266-275. doi: 10.1016/j.jcyt.2023.12.002. Epub 2024 Jan 15. Cytotherapy. 2024. PMID: 38231165 Free article.
Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion.
Mazumdar A, Poage GM, Shepherd J, Tsimelzon A, Hartman ZC, Den Hollander P, Hill J, Zhang Y, Chang J, Hilsenbeck SG, Fuqua S, Kent Osborne C, Mills GB, Brown PH. Mazumdar A, et al. Among authors: fuqua s. Breast Cancer Res Treat. 2016 Aug;158(3):441-54. doi: 10.1007/s10549-016-3892-y. Epub 2016 Jul 8. Breast Cancer Res Treat. 2016. PMID: 27393618 Free PMC article.
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models.
Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, Landis MD, Wiechmann L, Schiff R, Giuliano M, Wong H, Fuqua SW, Contreras A, Gutierrez C, Huang J, Mao S, Pavlick AC, Froehlich AM, Wu MF, Tsimelzon A, Hilsenbeck SG, Chen ES, Zuloaga P, Shaw CA, Rimawi MF, Perou CM, Mills GB, Chang JC, Lewis MT. Zhang X, et al. Among authors: fuqua sw. Cancer Res. 2013 Aug 1;73(15):4885-97. doi: 10.1158/0008-5472.CAN-12-4081. Epub 2013 Jun 4. Cancer Res. 2013. PMID: 23737486 Free PMC article.
PKMYT1 is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer.
Chen A, Kim BJ, Mitra A, Vollert CT, Lei JT, Fandino D, Anurag M, Holt MV, Gou X, Pilcher JB, Goetz MP, Northfelt DW, Hilsenbeck SG, Marshall CG, Hyer ML, Papp R, Yin SY, De Angelis C, Schiff R, Fuqua SAW, Ma CX, Foulds CE, Ellis MJ. Chen A, et al. Among authors: fuqua saw. Mol Cancer Ther. 2024 May 23. doi: 10.1158/1535-7163.MCT-23-0564. Online ahead of print. Mol Cancer Ther. 2024. PMID: 38781103
Metabolomic Rewiring Promotes Endocrine Therapy Resistance in Breast Cancer.
Ahn S, Park JH, Grimm SL, Piyarathna DWB, Samanta T, Putluri V, Mezquita D, Fuqua SAW, Putluri N, Coarfa C, Kaipparettu BA. Ahn S, et al. Among authors: fuqua saw. Cancer Res. 2024 Jan 16;84(2):291-304. doi: 10.1158/0008-5472.CAN-23-0184. Cancer Res. 2024. PMID: 37906431
206 results